Elyton Capital

Managing Director Michael Humber leads all investment decisions. Humber brings over fifteen years of operating and investing experience — from Series A rounds through 100% control buyouts — gained at a multi-billion-dollar family-owned holding company. The firm's three Operating Partners (Belcher, Gandhi, Saag) provide sector-specific diligence and portfolio-company support but the firm does not disclose an investment committee beyond Humber.

Elyton structures each investment as an independent holding rather than through a commingled fund. The firm can provide minority or majority equity and states explicitly that there is no predetermined exit time frame. This means a given deal is not subject to the 5–7 year realization pressure typical of traditional private equity funds.

Elyton Operating Partner Vishal Gandhi is the founding Managing Director of Keval Health, a boutique healthcare M&A advisory firm with offices in Los Angeles and New York City. Keval provides a proprietary sourcing and diligence channel into healthcare-technology and services deals for Elyton, though the two entities remain operationally distinct.

Elyton describes itself as a private capital group, not a private equity fund, and does not publicly indicate it manages commingled third-party LP capital. The firm's independent-deal structure suggests it operates predominantly with its own balance sheet or deal-by-deal co-investor relationships, but it has not disclosed its funding sources publicly.

The firm's website confines its stated focus to healthcare technology, value-added distribution, and niche manufacturing. There is no mention of sectors such as consumer internet, financial services, media, energy, or real estate. The absence of these verticals combined with the narrowly articulated focus implies deliberate exclusion.